Two Sigma Advisers
INDP icon

Two Sigma Advisers’s Indaptus Therapeutics INDP Stock Holding History

Two Sigma Advisers’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-39
Closed -$25K – 2506
2020
Q2 		$25K Buy
39
+30
+333% +$18.5K ﹤0.01% 2452
2020
Q1 		$4K Hold
9
– – ﹤0.01% 2439
2019
Q4 		$10K Sell
9
-1
-10% -$1.38K ﹤0.01% 2335
2019
Q3 		$16K Buy
10
+3
+43% +$8.93K ﹤0.01% 2188
2019
Q2 		$67K Buy
+7
New +$88.3K ﹤0.01% 2240

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Two Sigma Advisers's INDP Position: Q3 2020 in Review

Two Sigma Advisers sold out of Indaptus Therapeutics (INDP) in Q3 2020, closing a stake of 39 shares — an estimated $25K sold.

Two Sigma Advisers first reported a position in INDP in Q2 2019 and held it in 5 quarters. The position peaked at $67K in Q2 2019. 24 funds tracked by Wall St. Rank hold INDP as of Q3 2020.

  • Two Sigma Advisers reported no remaining Indaptus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 39 Indaptus Therapeutics shares in Q3 2020, an estimated $25K.
  • Two Sigma Advisers first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 5 quarters.
  • Two Sigma Advisers's Indaptus Therapeutics position peaked at $67K in Q2 2019.
  • 24 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2020.

Based on Two Sigma Advisers's 13F filing for Q3 2020, filed 16 Nov 2020.